Predict your next investment

HEALTHCARE | Biotechnology
convoytx.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$2M

About Convoy Therapeutics

Convoy Therapeutics is a biotechnology company focused on enhancing delivery of pharmaceuticals and macromolecules into the dermal layer of the skin for the treatment of psoriasis, atopic dermatitis, and malignant melanoma. Convoy's platform technology enables large and small molecules to penetrate and remain localized in the skin. The company has preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised internally for clinical development.

Convoy Therapeutics Headquarter Location

4262 Blue Diamond Road Suite 102-270

Las Vegas, Nevada, 89139,

United States

702-448-1826

Latest Convoy Therapeutics News

CTX Acquires Promising Proprietary Drug Delivery Assets

Aug 4, 2015

TA Instruments acquires assets of Bose Electroforce Group Built on peptide-based skin -penetration platform technology developed in the laboratory of Samir Mitragotri, PhD, at the University of California Santa Barbara, the Convoy Therapeutics assets include proprietary formulations for both therapeutic and aesthetic applications. The proprietary peptide platform technology is uniquely capable of transporting small and large molecules, with a wide range of molecular weights, including biologics , into the skin and ensuring that they remain at the site of local placement. The technology represents a new approach for improved topical delivery of a wide range of active ingredients. Of the proprietary formulations acquired, Khalay HATM, a formulation of hyaluronic acid, has shown superior moisturizing and wrinkle-reduction performance for aesthetic applications. CyclopsorbTM is a promising disease-modifying therapeutic that targets mild-to-moderate psoriasis. Both formulations utilize the CTX peptide-based skin-penetration platform technology. CTX will commercialize the existing proprietary formulations through focused partnerships, continue to work on new applications and out-license the platform technology for the therapeutic and aesthetic markets. View source version on businesswire.com: http://www.businesswire.com/news/home/20150804006520/en/ CTX Technology Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Convoy Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Convoy Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Convoy Therapeutics Patents

Convoy Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/11/2013

Membrane biology, Molecular biology, Cell biology, Biotechnology, Clusters of differentiation

Application

Application Date

2/11/2013

Grant Date

Title

Related Topics

Membrane biology, Molecular biology, Cell biology, Biotechnology, Clusters of differentiation

Status

Application

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.